Boehringer Ingelheim and AbGenomics Corporation sign worldwide exclusive collaboration and license agreement
Boehringer Ingelheim International GmbH and AbGenomics Corporation announced that they have signed an exclusive licensing agreement providing Boehringer Ingelheim with the worldwide exclusive rights to develop, manufacture and commercialize any products with AbGenomics Corporation's antibody 168. Based on data generated by AbGenomics Corporation, antibody 168 may potentially be developed to treat a broad range of immune-related diseases. The initial focus of the development will be on therapies for autoimmune diseases. Specific terms of the transaction were not disclosed but they are comparable to the average licensing deals for compound of a similar stage and market potential. Also, AbGenomics Corporation has an option to co-promote in selected Asian countries.
"Monoclonal antibodies are an increasingly important component of medical treatments. AbGenomics Corporation's antibody 168, with its novel mechanism of action, has the potential of introducing a new therapeutic paradigm for the treatment of autoimmune diseases. Our agreement with AbGenomics Corporation is the latest example of our corporate strategy to build long-term growth by focusing on biopharmaceuticals and on potential disease areas with unmet medical needs." said Dr Andreas Barner Vice Chairman of the Board Corporate Division Pharma Research, Development and Medicine at Boehringer Ingelheim.
"This licensing deal underlines our strategy of collaborating with international pharma partners who bring specialized skills and know-how to accelerate the development and marketing of our compounds. Boehringer Ingelheim, an outstanding company with world-class pharmaceutical business and a world leader in the manufacturing of biopharmaceuticals, is an ideal partner. We are enthusiastic about working with Boehringer Ingelheim and are also very optimistic that this agreement will bring our proprietary monoclonal antibody to patients around the world" commented Dr Rong-Hwa Lin, Chairman of the Board and Chief Executive Officer of AbGenomics Corporation.
Topics
Organizations
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
![Topic world Antibodies](http://static.chemie.de//media/images/focuspage/022d2694-7e7f-411e-9219-c2cf6ea89d36.png)
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous